Sep 21 2007, 8:33 AM EST
News source: Business Wire
Urigen Pharmaceuticals, Inc. (OTCBB: URGP), a specialty pharmaceutical company focused on the development and commercialization of treatments for urological disorders, was issued an additional patent relating to Urethral Suppositories by the U.S. Patent and Trademark Office. This patent expires August 30, 2021.
The patent number 7,267,670 broadens protection for Urigen's urethral suppository program to include a reinforced female urethral suppository platform.
"This new patent strengthens Urigen's intellectual property portfolio demonstrating Urigen's commitment to providing novel treatment approaches for urological disorders," comments William J. Garner, M.D., President and CEO of Urigen Pharmaceuticals, Inc. "In the highly competitive specialty pharmaceutical industry, a strong proprietary position is critical to commercial success. This patent is another step forward in our program to build such a proprietary position."
The claims of U.S. Patent number 7,267,670 describe the design and composition of reinforced urethral suppositories, which deliver one or more therapeutic agents to the female urinary tract.
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen's URG101 project targets painful bladder syndrome/interstitial cystitis, which affects approximately 10.5 million men and women in North America. Urigen's URG301 project targets acute urgency in patients diagnosed with an overactive bladder, another major unmet need that is insufficiently managed by presently available overactive bladder drugs. URG301 is a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency. For further information, please visit Urigen's website at http://www.urigen.com.
Forward-Looking Statement
This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, please review our SEC filings.
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All